Compare BKE & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKE | SUPN |
|---|---|---|
| Founded | 1948 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 1996 | 2010 |
| Metric | BKE | SUPN |
|---|---|---|
| Price | $50.75 | $53.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $55.00 | ★ $61.60 |
| AVG Volume (30 Days) | 308.0K | ★ 748.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $1,217,689,000.00 | $392,755,000.00 |
| Revenue This Year | $7.42 | $23.19 |
| Revenue Next Year | $2.75 | $17.65 |
| P/E Ratio | $20.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.12 | $29.16 |
| 52 Week High | $61.69 | $59.68 |
| Indicator | BKE | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 55.71 |
| Support Level | $47.15 | $47.95 |
| Resistance Level | $56.56 | $58.67 |
| Average True Range (ATR) | 1.48 | 2.33 |
| MACD | -0.16 | 0.13 |
| Stochastic Oscillator | 15.79 | 41.87 |
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.